These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551 [TBL] [Abstract][Full Text] [Related]
4. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Ueki N; Miyake K; Kusunoki M; Shindo T; Kawagoe T; Futagami S; Tsukui T; Inagaki H; Sakamoto C Helicobacter; 2009 Apr; 14(2):91-9. PubMed ID: 19298336 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study. Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938 [TBL] [Abstract][Full Text] [Related]
6. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326 [TBL] [Abstract][Full Text] [Related]
7. 'Rescue' therapies for the management of Helicobacter pylori infection. Di Mario F; Cavallaro LG; Scarpignato C Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140 [TBL] [Abstract][Full Text] [Related]
9. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366 [TBL] [Abstract][Full Text] [Related]
10. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X; J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P Digestion; 2013; 88(1):33-45. PubMed ID: 23880479 [TBL] [Abstract][Full Text] [Related]
12. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X; Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498 [TBL] [Abstract][Full Text] [Related]
13. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716 [TBL] [Abstract][Full Text] [Related]
14. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Gisbert JP; Calvet X Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241 [TBL] [Abstract][Full Text] [Related]
16. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Gisbert JP; Castro-Fernández M; Bermejo F; Pérez-Aisa A; Ducons J; Fernández-Bermejo M; Bory F; Cosme A; Benito LM; López-Rivas L; Lamas E; Pabón M; Olivares D; Am J Gastroenterol; 2006 Feb; 101(2):243-7. PubMed ID: 16454825 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Dib J; Alvarez B; Mendez L; Cruz ME Arab J Gastroenterol; 2013 Sep; 14(3):123-5. PubMed ID: 24206741 [TBL] [Abstract][Full Text] [Related]
18. [What is currently the Helicobacter pylori eradication therapy of choice? Triple therapy (PPI, amoxicillin and clarithromycin) or sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and metronidazole for a further 5 days)?]. Sánchez-Delgado J Gastroenterol Hepatol; 2009 Jan; 32(1):68-9. PubMed ID: 19174106 [No Abstract] [Full Text] [Related]
19. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805 [TBL] [Abstract][Full Text] [Related]
20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]